Clinical outcomes of thoracic radiotherapy in combination with chemoimmunotherapy in elderly patients with extensive‐stage small cell lung cancer
Precision Radiation Oncology · 2026-03 · 10 (1) · 39-47
DOI: 10.1002/pro6.70051 ↗Kurz gefasst
Fachartikel in der Zeitschrift Precision Radiation Oncology, online erschienen am 11.03.2026. Verfasst von Jinmin Han und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy Yantai Yuhuangding Hospital Affiliated to Qingdao University Yantai Shandong China. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Purpose
We evaluated the effect of thoracic radiotherapy (TRT) on extensive‐stage small‐cell lung cancer (ES‐SCLC) in elderly patients (aged ≥ 60 years) in the era of immunotherapy (IO) and analyzed the prognostic factors to guide personalized treatment.
Methods
The clinical data of 178 elderly patients were reviewed. Kaplan‐Meier curves were generated to estimate the survival rates. Multivariate prognostic analyses were performed using Cox proportional hazards models.
Results
The mOS in the CRT‐IO group was superior to that in the CT‐IO group (22.0 vs. 14.7 months, p = 0.014). In addition, the mPFS in the CRT‐IO group was significantly longer than that in the CT‐IO group (11.2 vs. 7.0 months, p = 0.023). The mOS in the CRT‐IO group was better than that in the CRT group; however, the difference was not statistically significant (22.0 vs. 17.3 months, p = 0.103). Overall survival was the longest in the CRT‐IO group, followed by the CRT and CT‐IO groups.Patients in the low‐dose group had longer survival times than those in the high‐dose group; however, this difference was not statistically significant (all p > 0.05).Multivariate analysis suggested that a KPS (Karnofsky performance status) score ≥ 80 ( p = 0.003) was a good predictor of longer OS, whereas liver metastasis ( p = 0.004) was associated with shorter OS.
Conclusions
CRT‐IO should be prioritized as a treatment for elderly patients with ES‐SCLC with good performance status and liver metastasis. However, CRT could be a viable option for patients with a compromised performance status or for whom economic factors are a concern.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiotherapy Yantai Yuhuangding Hospital Affiliated to Qingdao University Yantai Shandong China.
- Department of Pharmacy Lijin County Central Hospital Dongying Shandong China.
- Department of Medical Affairs Yantai Yuhuangding Hospital Affiliated to Qingdao University Yantai Shandong China.
- Department of Gastroenterology Ward Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan Shandong China.
- Department of Radiation Oncology Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan Shandong China.
- Present/permanent address: Department of Radiation Oncology Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan Shandong China.
ORCID-Profile: Chengxin Liu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Han, J., Zheng, W., Jiang, J., Shi, H., & Liu, C. (2026). Clinical outcomes of thoracic radiotherapy in combination with chemoimmunotherapy in elderly patients with extensive‐stage small cell lung cancer. Precision Radiation Oncology, 10(1), 39-47. https://doi.org/10.1002/pro6.70051
Vancouver
Han J, Zheng W, Jiang J, Shi H, Liu C. Clinical outcomes of thoracic radiotherapy in combination with chemoimmunotherapy in elderly patients with extensive‐stage small cell lung cancer. Precision Radiation Oncology. 2026;10(1):39-47. doi:10.1002/pro6.70051
BibTeX
@article{Han2026,
author = {Han, Jinmin and Zheng, Wencai and Jiang, Jie and Shi, Huan and Liu, Chengxin},
title = {Clinical outcomes of thoracic radiotherapy in combination with chemoimmunotherapy in elderly patients with extensive‐stage small cell lung cancer},
journal = {Precision Radiation Oncology},
year = {2026},
volume = {10},
number = {1},
pages = {39--47},
doi = {10.1002/pro6.70051}
}
EUVIMED